Liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapy
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite Claude Bernard Lyon 1, Hospices Civils De Lyon, Centre Leon Berard
InventorsCharles Dumontet, Abdelkamel Chettab
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.
Claims15
A pharmaceutical combination product for a human comprising:
- a liposomal formulation consisting of one or more liposomes each encapsulating only a bacterial lipopolysaccharide (LPS) as a single active ingredient and containing no antigen;
- and
- at least one cytotoxic compound chosen from the group consisting of:
- the therapeutic antibody rituximab,
- a chemotherapeutic agent chosen from the group consisting of:
- etoposide and doxorubicin.
A method for treating a tumor comprising administering to a human patient having said tumor an effective amount of a liposomal formulation consisting of:
- (1) one or more liposomes each encapsulating only a bacterial lipopolysaccharide as a single active ingredient and containing no antigen;
- and
- (2) at least one cytotoxic compound chosen from the group consisting of:
- the therapeutic antibody rituximab,
- a chemotherapy agent chosen from the group consisting of:
- etoposide and doxorubicin.
Dependencies are inferred from the claim text.